tbuckley/cabot-search huggingface dataset:
Surveillance and laboratory detection for non-polio enteroviruses in the European Union/European Economic Area, 2016
Authors: Heli Harvala, Aftab Jasir, Pasi Penttinen, Lucia Pastore Celentano, Donato Greco, Eeva Broberg
Journal: Eurosurveillance (2017)

Enteroviruses (EVs) cause severe outbreaks of respiratory and neurological disease as illustrated by EV-D68 and EV-A71 outbreaks, respectively. We have mapped European laboratory capacity for identification and characterisation of non-polio EVs to improve preparedness to respond to (re)-emerging EVs linked to severe disease. An online questionnaire on non-polio EV surveillance and laboratory detection was submitted to all 30 European Union (EU)/European Economic Area (EEA) countries. Twenty-nine countries responded; 26 conducted laboratory-based non-polio EV surveillance, and 24 included neurological infections in their surveillance. Eleven countries have established specific surveillance for EV-D68 via sentinel influenza surveillance (n = 7), typing EV-positive respiratory samples (n = 10) and/or acute flaccid paralysis surveillance (n = 5). Of 26 countries performing non-polio EV characterisation/typing, 10 further characterised culture-positive EV isolates, whereas the remainder typed PCR-positive but culture-negative samples. Although 19 countries have introduced sequence-based EV typing, seven still rely entirely on virus isolation. Based on 2015 data, six countries typed over 300 specimens mostly by sequencing, whereas 11 countries characterised under 50 EV-positive samples. EV surveillance activity varied between EU/EEA countries, and did not always specifically target patients with neurological and/or respiratory infections. Introduction of sequence-based typing methods is needed throughout the EU/EEA to enhance laboratory capacity for the detection of EVs.
Abstract #5582: Itraconazole as a novel Hedgehog pathway antagonist in cancer therapy
Authors: James Kim, Ruoyu Gong, John Lee, Curtis Chong, Karl Clemons, Jun Liu, David Stevens, Philip Beachy
Journal: Cancer Research (2009)

Inappropriate activity of the Hedgehog (Hh) signaling pathway has been linked to a variety of tumor types. Cyclopamine and other small molecules have been found to antagonize Hh pathway activity. These small molecules have been effective in blocking Hh pathway-dependent growth of transformed cells, both in vitro and in vivo, thus stimulating major efforts to develop small molecule antagonists of the Hh pathway as novel cancer therapeutics. To accelerate this process, we have screened a library of compounds previously tested in humans. Here we report that the triazole itraconazole, a commonly used systemic antifungal, is a potent Hh pathway antagonist. Itraconazole acts to inhibit pathway activity downstream of Patched, but by a mechanism distinct from that of cyclopamine and other Smoothened antagonists. Its mechanism of Hh pathway inhibition is also distinct from its antifungal effect on sterol biosynthesis. Systemically administered itraconazole, like other Hh pathway antagonists, can suppress the growth of medulloblastoma in a mouse allograft model. The serum levels of itraconazole required for these anti-tumor effects in mice are comparable to those achieved in patients undergoing high dose systemic therapy for fungal infections, thus indicating that itraconazole may be rapidly tested for the treatment of Hh pathway-dependent cancers.   Citation Information:  In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 5582.
Linee guida europee per il controllo e la prevenzione della malattia dei legionari associata ai viaggi: l'esperienza italiana
Authors: M C Rota, M R Caporali, M Massari
Journal: Eurosurveillance (2004)

In Italia, nel periodo luglio 2002-ottobre 2003, dopo l'adozione delle linee guida europee, sono stati identificati 35 cluster di malattia dei legionari associata ai viaggi. Tra questi, otto (28,6%) non sarebbero stati identificati senza la rete di sorveglianza EWGLINET. 
Delle 35 strutture notificate, 30 erano alberghi/residence e 5 campeggi con un numero di casi in ogni struttura compreso tra due e sei, per un totale di 87 pazienti coinvolti. La diagnosi di malattia dei legionari e stata confermata nel 92,0% dei casi ed effettuata prevalentemente mediante isolamento dell'antigene solubile urinario (84,7%). In un solo caso era disponibile il ceppo isolato da un campione biologico. 
L'indagine ambientale e stata effettuata in tutte le 35 strutture recettive associate con un cluster, e Legionella pneumophila e stata rilevata in 23 casi (65,7%). 
In 15 delle 35 strutture recettive, le indagini erano gia in corso quando lo EWGLI ha notificato il cluster, dato che in Italia indagini ambientali complete vengono effettuate anche dopo la notifica di un singolo caso. 
Idonee misure di controllo sono state intraprese in tutte le strutture a rischio e un solo albergo e stato chiuso. 
Per tutti i 35 cluster, le relazioni preliminari e finali sono state completate ed inviate in tempo allo EWGLI, dimostrando che e possibile rispettare le procedure richieste dalle linee guida europee.
DRES-13. RETINOBLASTOMA BINDING PROTEIN 4 (RBBP4) INTERACTS WITH p300 TO REGULATE DNA REPAIR AND APOPTOSIS GENES IN GLIOBLASTOMA
Authors: Gaspar Kitange, Ann Mladek, Brett Carlson, Katrina Bakken, Huihuang Yan, Jann Sarkaria
Journal: Neuro-Oncology (2017)

Recently, we have demonstrated that RBBP4 interacts with p300 to regulate MGMT and the homologous recombination repair genes RAD51, EYA1 and FIGNL1 in glioblastoma (GBM) cells. To gain insight into the genes regulated by the RBBP4/p300 complex, we have extended the above findings by performing RNAseq in patient derived xenograft (PDX) GBM43 cells with shRNA knockdown of RBBP4 or p300 and a control non-specific targeting construct (NT). Overall, silencing RBBP4 and p300 altered the expression of 4,696 genes, with upregulation of 2,644 (57%) genes and downregulation of 2052 (43%) genes. A total of 719 (35%) were coordinately downregulated by silencing either RBBP4 or p300, suggesting that these genes may be controlled by the RBBP4/p300 complex. A total of 42 (6%) of the downregulated genes were classified as DNA damage repair (DDR) genes. Interestingly, 31 of these genes function in a network connecting multiple DDR pathways. Parallel ChIPseq revealed that RBBP4 or p300 silencing decreased H3K27Ac and/or H3K9Ac within promoters of 34 of these genes suggesting histone acetylation, perhaps by p300, as the key mechanism by which RBBP4/p300 regulates these DDR genes. Interestingly, silencing RBBP4 or p300 coordinately suppressed 131 genes involved in cell death and survival, and 33 of these genes are connected in a network known to regulate apoptosis in brain tumor cells, including BCL2, BIRC2, BIRC3 and MYC. Collectively, these findings suggest that the RBBP4/p300 complex plays a critical role not only in the repair of DNA damage but may also govern the ability of cells to undergo apoptotic cell death. Even though further studies are still in progress to link RBBP4/p300 with DDR and apoptosis, we conclude that this complex possibly controls multiple DDR and apoptotic pathways and manipulation of this complex could sensitize therapy in GBM and perhaps in other human cancers in general.
Gene-expression profiles of primary and metastatic lesions in head and neck squamous cell carcinoma
Authors: S. Alfieri, P. Bossi, D. Galbiati, M. Giannoccaro, S. Pilotti, F. Perrone, N. Paielli, L. Tonella, C. Bergamini, R. Granata, C. Resteghini, S. Cavalieri, N.A. Iacovelli, E. Orlandi, L.D. Locati, L. Licitra, S. Canevari, L. De Cecco
Journal: Annals of Oncology (2017)
The Black Panther, From Politics to Popular Culture
Authors: Chetan Ambastha, Anshum Sood, Stephanie Steinweg
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
TMOD-35. THERAPEUTIC APPLICATIONS OF A THREE-DIMENSIONAL ORGANOID CULTURE SYSTEM DERIVED FROM GLIOBLASTOMA STEM CELLS
Authors: Pratik Kanabur, Zhi Sheng
Journal: Neuro-Oncology (2017)

Glioblastoma (GBM) growth and therapeutic resistance are driven by glioblastoma stem cells (GSC), which reside at the apex of the tumor hierarchy and rely on the complex interactions in the tumor microenvironment. Standard cell culture conditions fails to recapitulate the original architecture, hitopathologic diversity, and the inter-tumoral heterogeneity of the original patient tumor. To use GSCs isolated from surgically resected tumors, established cell lines, or tumor xenografts to create a three-dimensional culture system that supports the long-term growth and expansion of tumor organoids and gauge the therapeutic response to temozolomide. Surgically resected tumor was digested and individual tumor cells were isolated and incubated in serum-free stem cell media. Established cell lines and tumor xenografts were also grown in serum free stem cell media. Spheres were then dissociated and mixed with matrigel matrix and grown in culture. The growth of the organoids was monitored and assessed using microscopy. Verified organoids were tested for response to temozolomide. Glioblastoma stem cells were able to form organoids. Established cell line LN229/GSC, tumor xenograft GBM10, and patient derived stem cell lines VTC 034 and VTC 036 were able to form organoids that were visible without microscopy at 4, 3, 5, and 7 weeks, respectively. VTC 034 organoids were selected for treatment. The size of the organoid was decreased after treatment with temozolmide. Glioblastoma organoid formation is a novel ex vivo method in which different glioblastoma stem cell lines can be cultured and is a worthy model to monitor therapeutic efficacy of drug treatment.
A Special Report on the NHLBI Initiative to Study Cellular and Molecular Mechanisms of Arterial Stiffness and Its Association With Hypertension
Authors: Young S. Oh, Dan E. Berkowitz, Richard A. Cohen, C. Alberto Figueroa, David G. Harrison, Jay D. Humphrey, Douglas F. Larson, Jane A. Leopold, Robert P. Mecham, Nelson Ruiz-Opazo, Lakshmi Santhanam, Francesca Seta, John Y.J. Shyy, Zhongjie Sun, Philip S. Tsao, Jessica E. Wagenseil, Zorina S. Galis
Journal: Circulation Research (2017)
MA 19.09 The Role of Neoadjuvant Chemotherapy in Patients with Malignant Pleural Mesothelioma
Authors: S. Voigt, M. Joshi, P. Speicher, B. Tong, M. Onaitis, J. Crawford, T. D'Amico, D. Harpole
Journal: Journal of Thoracic Oncology (2017)
Abstract 17196: Incidence and Clinical Implications of Pneumonia in Comatose Survivors of Out-of-hospital Cardiac Arrest: Insights From University of Ottawa Heart Institute Cardiac Arrest Registry
Authors: Juan J Russo, Hany Rizk, Christina Osborne, Tyler E James, Benjamin Hibbert, Derek Y So, Michael Froeschl, Marino Labinaz, Chris Glover, Aun-Yeong Chong, Jean-Francois Marquis, Alexander Dick, Michel R Le May
Journal: Circulation (2016)

Background: Health-care associated pneumonia is a common complication in comatose survivors of out-of-hospital cardiac arrest (OHCA). However, the effect of pneumonia on the hospital course and cli...
OA 15.01 Lung Cancer Screening: Participant Selection by Risk Model – the Pan-Canadian Study
Authors: M. Tammemägi, H. Schmidt, S. Martel, A. Mcwilliams, J. Goffin, M. Johnston, G. Goss, A. Tremblay, R. Bhatia, G. Liu, K. Soghrati, K. Yasufuku, D. Hwang, F. Laberge, M. Gingras, S. Pasian, C. Couture, J.R. Mayo, P.V. Nasute Fauerbach, S. Atkar-Khattra, S.J. Peacock, S. Cressman, D. Ionescu, J.C. English, R.J. Finley, J. Yee, S. Puksa, L. Stewart, S. Tsai, E. Haider, C. Boylan, J. Cutz, D. Manos, Z. Xu, G. Nicholas, J.M. Seely, K. Amjadi, H.S. Sekhon, P. Burrowes, P. Maceachern, S. Urbanski, D. Sin, W.C. Tan, N. Leighl, F. Shepherd, W. Evans, M. Tsao, S. Lam
Journal: Journal of Thoracic Oncology (2017)
FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy
Authors: Anja Mottok, Vindi Jurinovic, Pedro Farinha, Andreas Rosenwald, Ellen Leich, German Ott, Heike Horn, Wolfram Klapper, Michael Boesl, Wolfgang Hiddemann, Christian Steidl, Joseph M. Connors, Laurie H. Sehn, Randy D. Gascoyne, Eva Hoster, Oliver Weigert, Robert Kridel
Journal: Blood (2017)
PALL-09. PSYCHOLOGICAL DISTRESS AND PROGNOSTIC UNDERSTANDING IN PATIENTS WITH MALIGNANT GLIOMAS AND THEIR CAREGIVERS
Authors: Deborah A Forst, Katharine M Quain, Kevin Poisson, Justin Eusebio, Vicki A Jackson, Joseph A Greer, Areej El-Jawahri, Jennifer S Temel
Journal: Neuro-Oncology (2017)

Patients with malignant gliomas have a poor prognosis and high symptom burden. The supportive care needs of this population and their families have not been well described. We evaluated depression, anxiety, and prognostic understanding in malignant glioma patients and their family caregivers. We conducted a longitudinal study in patients with newly diagnosed malignant glioma and their caregivers, collecting self-report data at diagnosis and 3, 6, and 9 months post-diagnosis. Depression and anxiety were assessed by the Hospital Anxiety and Depression Scale, with subscale scores >7 considered clinically significant. Prognostic understanding was evaluated with the Prognosis and Treatment Perception Questionnaire, starting at the 3-month time point. Accurate prognostic understanding was defined as responses of “unlikely,” “very unlikely” or “no” chance of cure. 21.7% (15/69) of patients and 26.8% (15/56) of caregivers experienced clinically significant depression symptoms at diagnosis, while 24.6% (17/69) of patients and 55.4% (31/56) of caregivers experienced significant anxiety symptoms. Rates of caregiver anxiety remained high over time, with more than 60% of caregivers reporting clinically significant anxiety at 6 and 9 months post-diagnosis. Although 81.0% (47/58) of patients and 86.0% (37/43) of caregivers reported that it was “extremely” or “very” important to know about prognosis, only 43.1% (25/58) of patients and 67.4% (29/43) of caregivers reported accurate prognostic understanding at 3 months. A significant proportion of patients with malignant gliomas have psychological distress at the time of diagnosis. Their caregivers experience even higher rates of psychological distress, with more than 50% reporting anxiety throughout the patients’ illness course. Interestingly, caregivers reported more accurate prognostic understanding than patients. Further research is needed to understand if this discordance in prognostic understanding contributes to caregiver distress. Interventions are needed to provide psychosocial support for these patients and caregivers and to improve communication about prognosis.
P1.02-032 Clinicopathological Profile of Invasive Mucinous Adenocarcinoma Based on Evaluation of Invasive Components
Authors: Y. Mitsui, H. Fushimi, Y. Tanio, K. Ueno, J. Uchida, M. Suzuki, Y. Shirai, K. Matsumoto, K. Kuno, T. Yanase, Y. Funakoshi, H. Takabatake, K. Shimazu, A. Kikuyama
Journal: Journal of Thoracic Oncology (2017)
NIMG-19. GLIOMA-LIKE INTRAPARENCHYMATOUS LESIONS ON MRI BRAIN IN ADULT NEUROFIBROMATOSIS TYPE 1 PATIENTS
Authors: Walter Taal, Bart Zick, Bart J Emmer, Corriene E Catsman-Berrevoets, Martin van den Bent
Journal: Neuro-Oncology (2017)

Neurofibromatosis Type 1 (NF1) is a neurocutaneous disorder with a highly increased risk of gliomas. In addition, unspecified T2 hyper intensities (Unidentified Bright Objects; UBOs) are often seen on the MRI brain which may disappear over time. The distinction between large UBOs and glioma is sometimes difficult. In addition, enhancing intraparenchymatous lesions have been described that disappear over time. As the incidence and evolution of these lesions have been insufficiently studied in NF1 adults, we conducted a retrospective study on this topic. All MRI brain scans and clinical data of all NF1 patients visiting the Erasmus MC between 1995 and 2016 were reviewed. Patients who underwent at least one MRI brain performed over the age of 18 were included for this study. MRI lesions and its evolution over time were analyzed. Glioma-like lesions (GLL) were defined as having mass effect and/or contrast enhancement. Six hundred and sixty-three MRI brain scans in 182 adult NF1 patients were reviewed with a mean follow-up of 2,5 years (range 0 – 27,7y). MRI lesions were found in 123 patients (68 %) and GLL were found in 38 patients (21%). Remarkably, contrast enhancement in 5 out of 27 enhancing GLL disappeared spontaneously and 2 of them also vanished completely during follow-up. Two GLL with mass effect only disappeared spontaneously. The majority of the other lesions decreased in size or remained stable with follow-up. Ten patients (5%) underwent a resection or biopsy because of progressive neurological symptoms and histology showed a WHO grade 1, 2, 3 or 4 glioma in 4, 2, 1 and 3 patients respectively. Asymptomatic GLL are common in adult NF1 patients and are often of indolent nature. Asymptomatic patients can be followed without invasive diagnostic and therapeutic procedures.
Um surto urbano de febre Q, Briançon, França, Março-Junho 1996
Authors: A Armengaud, N Kessalis, J C Desenclos, E Maillot, P Brousse, P Brouqui, H Tixier-Dupont, D Raoult, P Provensal, Y Obadia
Journal: Eurosurveillance (1997)

A febre Q e uma zoonose ubiqua provocada por uma rickettsia, Coxiella burnetii, ocorrendo como casos esporadicos em zonas de pastagem de ovinos e caprinos e podendo ser responsaveis por surtos humanos (1). O modo de transmissao predominante e a inalacao de aerossois infectados provenientes do meio ambiente (solo, palha, la), contaminado apos o periodo de parto do gado ovino, caprino ou bovino (1). Neste artigo, descrevemos um surto urbano de febre Q que ocorreu de Marco a Maio de 1996, em Briancon, uma cidade de 12 000 habitantes, situada numa zona de pastagem dos Hautes Alpes.
Abstract 13794: An Orally-Active Small-Molecule Antagonist of the Platelet Protease-Activated Receptor-4, BMS-986141, Prevents Aeterial Thrombosis With Low Bleeding Liability in Cynomolgus Monkeys
Authors: Pancras C Wong, Carol A Watson, Jeffery Bostwick, Jacques Banville, Ruth R Wexler, E S Priestley, Anne Marinier, Michel Bouvier, David Gordon, William Schumacher, Jing Yang
Journal: Circulation (2017)

Introduction: BMS-986141 (BMS) is a small-molecule platelet thrombin receptor antagonist selective for the protease-activated receptor-4 (PAR4), and is under clinical investigation. Hypothesis: Blo...
GENE-37. PATHWAY ANALYSIS OF RADIATION-INDUCED MENINGIOMAS REVEALS THAT TUMOURS WITH NF2-FUSION HAVE UPREGULATION OF INFLAMMATORY PATHWAYS
Authors: Suganth Suppiah, Sameer Agnihotri, Jeff Liu, Mamatjan Yasin, Ken Aldape, Gelareh Zadeh
Journal: Neuro-Oncology (2017)

As more pediatric cancer patients are surviving into adulthood from improved oncological therapy there is an increase in the long-term sequelae of treatment. Radiation-induced meningiomas (RIMs), one such secondary effect, demonstrate significantly different biology than sporadic meningiomas (SMs) and demonstrate clinically more aggressive behaviour. RIMs have been shown to not harbor mutations in common SM associated driver genes, such as NF2, TRAF7, KLF4, PIK3CA and SMO; however, a subset of RIMs have genomic rearrangements with NF2 gene fused to a reciprocal gene, which was previously not seen in SMs. We aimed to compare and contrast the gene expression in RIMs with and without the NF2-fusion event. A primary cohort of 7 RIMs with NF2-fusion and 12 RIMs with wildtype NF2 had RNA sequencing performed using the Illumina HiSeq platform. RNA-Seq expression profiles were analyzed using edgeR, available through BioConductor. Gene Set Enrichment Analysis was performed using Cytoscape®. Principle component analysis of the RNA-Seq data showed that 5/7 RIMs with NF2-fusion were similar to one another. One of the outliers was the only NF2-fusion RIM without a 1p chromosomal arm loss. Significant differentially expressed genes included IGF-1 (log2 of fold change or logFC = 4.14, p=2.65E-05), MME (logFC = 3.03, p = 3.56E-03) and MMP16(logFC = 2.47, p=8.14E-03). Notably, the pathway analysis demonstrated that there was an upregulation of immune/inflammation pathways involving PD-1, STAT-4, IGF-1 and other genes in RIMs with NF2-fusion compared to RIMs with NF2 wildtype. RIMs with the NF2-fusion event have a distinct gene expression profile, with upregulation of inflammatory pathways. Further studies need to be performed to validate these findings using immunohistochemistry. These results suggest that NF2-fusion RIMs may be candidates for immunotherapy.
P3.01-043 Impact of ErbB Mutations on Clinical Outcomes in Afatinib- or Erlotinib-Treated Patients with SCC of the Lung
Authors: G. Goss, E. Felip, M. Cobo, S. Lu, K. Syrigos, K.H. Lee, E. Göker, V. Georgoulias, W. Li, S. Guclu, D. Isla, Y. Joo Min, A. Morabito, A. Ardizzoni, S. Gadgeel, N. Gibson, N. Krämer, F. Solca, A. Cseh, E. Ehrnrooth, J. Soria
Journal: Journal of Thoracic Oncology (2017)